

Article

# Variants Affecting the C-Terminal Tail of UNC93B1 Are Not a Common Risk Factor for Systemic Lupus Erythematosus

Sarah Kiener <sup>1,2</sup> , Camillo Ribi <sup>3</sup> , Irene Keller <sup>4</sup>, Carlo Chizzolini <sup>5</sup> , Marten Trendelenburg <sup>6</sup>, Uyen Huynh-Do <sup>7</sup> , Johannes von Kempis <sup>8</sup>, on behalf of Swiss SLE Cohort Study (SSCS) <sup>†</sup> and Tosso Leeb <sup>1,2,\*</sup> 

- <sup>1</sup> Institute of Genetics, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland; sarah.kiener@vetsuisse.unibe.ch
- <sup>2</sup> Dermfocus, University of Bern, 3001 Bern, Switzerland
- <sup>3</sup> Division of Immunology and Allergy, Department of Medicine, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), 1011 Lausanne, Switzerland; camillo.ribi@chuv.ch
- <sup>4</sup> Interfaculty Bioinformatics Unit, University of Bern, 3012 Bern, Switzerland; irene.keller@dbmr.unibe.ch
- <sup>5</sup> Department of Pathology and Immunology, School of Medicine, Geneva University, 1211 Geneva, Switzerland; carlo.chizzolini@unige.ch
- <sup>6</sup> Laboratory for Clinical Immunology, Department of Biomedicine and Division of Internal Medicine, University Hospital of Basel, 4031 Basel, Switzerland; marten.trendelenburg@usb.ch
- <sup>7</sup> Division of Nephrology and Hypertension, Inselspital, Bern University Hospital, 3010 Bern, Switzerland; Uyen.Huynh-Do@insel.ch
- <sup>8</sup> Division of Rheumatology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland; Johannes.VonKempis@kssg.ch
- \* Correspondence: toso.leeb@vetsuisse.unibe.ch; Tel.: +41-31-684-2326
- <sup>†</sup> Association of the Swiss SLE Cohort Study (ASSCS), 4031 Basel, Switzerland.



**Citation:** Kiener, S.; Ribi, C.; Keller, I.; Chizzolini, C.; Trendelenburg, M.; Huynh-Do, U.; von Kempis, J.; on behalf of Swiss SLE Cohort Study (SSCS); Leeb, T. Variants Affecting the C-Terminal Tail of UNC93B1 Are Not a Common Risk Factor for Systemic Lupus Erythematosus. *Genes* **2021**, *12*, 1268. <https://doi.org/10.3390/genes12081268>

Academic Editor: Katsushi Tokunaga

Received: 5 July 2021

Accepted: 8 August 2021

Published: 19 August 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Abstract:** Systemic lupus erythematosus (SLE) is a heterogeneous multifactorial disease. Upregulated TLR7 signaling is a known risk factor for SLE. Recently, it was shown that specific genetic variants in *UNC93B1* affect the physiological regulation of TLR7 signaling and cause characteristic autoimmune phenotypes with monogenic autosomal recessive inheritance in mutant mice and dogs. We therefore hypothesized that homologous variants in the human *UNC93B1* gene might be responsible for a fraction of human SLE patients. We analyzed 536 patients of the Swiss SLE Cohort Study for the presence of genetic variants affecting the C-terminal tail of UNC93B1. None of the investigated patients carried bi-allelic *UNC93B1* variants that were likely to explain their SLE phenotypes. We conclude that genetic variants affecting the C-terminal tail of UNC93B1 are not a common risk factor for SLE. It cannot be excluded that such variants might contribute to other heritable autoimmune diseases.

**Keywords:** *Homo sapiens*; immunology; autoimmunity; candidate gene; TLR7 signaling

## 1. Introduction


SLE (Systemic Lupus Erythematosus) is a highly complex and heterogenous autoimmune disease with incompletely understood etiopathology [1,2]. Age of onset, specific organs affected, and the severity of the disease are highly variable between patients. SLE is characterized by a breakdown in immune tolerance, which promotes the formation of autoreactive B and T cells, abnormal cytokine production, and the subsequent generation of autoantibodies against DNA- and RNA-based self-antigens [2]. Women are nine times more frequently affected than men, and the incidence of the disease is highest in women of childbearing age [3].

SLE is thought to be caused by interactions between susceptibility genes and environmental factors resulting in an irreversible loss of immunologic self-tolerance. Several GWAS identified more than 100 risk loci for SLE, including associations to the HLA locus and many non-coding and presumably regulatory genome regions [4,5]. The X-chromosomal *TLR7* gene encoding toll-like receptor 7 is one of the confirmed risk loci for SLE [5]. Increased TLR7 activity promotes autoimmunity [6–8], and there are indications that partial

escape of *TLR7* from X-chromosome inactivation may contribute to the extreme sex-bias in SLE incidence [9]. A single nucleotide variant in the 3'-UTR, rs3853839, modulates *TLR7* expression and has been repeatedly associated with SLE [10,11].

While SLE is a genetically highly complex disease, rare patients exist in which SLE or related autoimmune disorders are caused by single-gene defects. Genes affected in such patients include *DNASE1* [12] and *TREX1* [13].

*TLR7* is activated by single-stranded RNA and represents a component of the innate immune defense against RNA viruses. The trafficking chaperone *UNC93B1* is required for the correct localization of *TLR7* to endosomal membranes, and its loss-of-function leads to an immune deficiency [14–16]. *TLR7* and *UNC93B1* form a heterotetrameric complex in a 2:2 stoichiometry in endosomal membranes [17]. Subsequent to *TLR7* activation, syndecan binding protein (SDCBP) binds to the C-terminal tail of *UNC93B1*, which induces the termination of *TLR7* signaling [18]. Genetic variants in *UNC93B1* that prevent SDCBP binding without affecting other functions of *UNC93B1* result in the disruption of this negative feedback loop and consequently overactive *TLR7* signaling that will eventually be triggered by endogenous RNA molecules [18–21]. *Unc93b1*<sup>PKP/PKP</sup> mice with a targeted disruption of the SDCBP binding motif develop a fatal systemic inflammation and autoimmune disease [18]. In dogs, a spontaneous missense variant affecting the C-terminal tail of *UNC93B1* causes exfoliative cutaneous lupus erythematosus (ECLE) [22]. ECLE starts with skin lesions but typically develops into a systemic form of lupus in the affected dogs [22–26] (Figure 1).



**Figure 1.** Topology of the human *UNC93B1* protein. (A) *UNC93B1* comprises 597 amino acids and contains 12 transmembrane domains. A segment of the C-terminal tail indicated in red is required for the interaction with SDCBP and subsequent dampening of *TLR7* signaling [18]. (B) Amino acid sequence from position 521 to 553. Substitution of a highly conserved proline with threonine causes exfoliative cutaneous lupus erythematosus in dogs [22]. Targeted mutagenesis of the four underlined motifs disrupted SDCBP binding in mouse macrophages [18]. A targeted mouse mutant, *Unc93b1*<sup>PKP/PKP</sup>, in which the residues corresponding to the human positions 530–532 were replaced by alanines, developed systemic inflammation and autoimmunity [18].

Based on the recent insights about *UNC93B1* function and the phenotypes in *UNC93B1* mutant mice and dogs, we hypothesized that genetic variants affecting the C-terminal tail of *UNC93B1* might also be responsible for SLE or related autoimmune disease in human patients. We therefore investigated the sequence of the last exon of the *UNC93B1* gene in patients of the Swiss SLE Cohort Study.

## 2. Materials and Methods

### 2.1. Patient Selection and DNA Extraction

This study included 536 patients of the Swiss SLE Cohort Study (SSCS). Of the patients, 457 (85%) were female and 414 (78%) of European descent. In 497 (93%) of patients, SLE was diagnosed after the age of 18 years. Details about this cohort have been reported previously [27–29]. Genomic DNA was isolated from EDTA blood samples with the Maxwell RSC Whole Blood Kit using a Maxwell RSC instrument (Promega, Dübendorf, Switzerland).

## 2.2. *UNC93B1* Targeted Sanger Sequencing

A 1000 bp PCR amplicon was amplified with primers AAGGGACAGTGCTGGATGTG (Primer F) and CAGGGCATCCGTGCATCC (Primer R). This amplicon contained 198 bp of the last intron of *UNC93B1*, 312 bp protein-coding region of the last exon and 490 bp of the 3'-UTR. The protein-coding part corresponded to codons 495 to 597 of the open reading frame. PCRs were performed in 10 µL total volume containing 10 ng template DNA, 5 pmol of each primer, 5 µL AmpliTaqGold360Mastermix, and 1 µL of GC enhancer (Thermo Fisher Scientific, Waltham, MA, USA). A touchdown PCR was performed with an initial denaturation for 10 min at 95 °C, followed by 5 cycles of 30 s denaturation at 95 °C, 30 s annealing at 65 °C with a decrease of 1 °C at each cycle, and 60 s polymerization at 72 °C. Subsequently, 30 cycles of 30 s denaturation at 95 °C, 30 s annealing at 60 °C and 60 s polymerization at 72 °C followed. At the end, a final extension step of 7 min at 72 °C was performed. After treatment with shrimp alkaline phosphatase and exonuclease I, PCR amplicons were sequenced with the forward primer F and reverse primer R1 (AGCTGTGGGGATCTGGAGC) on an ABI 3730 DNA Analyzer (Thermo Fisher Scientific). Sequencer 5.1 software was used to analyze the Sanger sequences (GeneCodes, Ann Arbor, MI, USA).

## 2.3. Whole Genome Sequencing

An Illumina TruSeq PCR-free DNA library with ~400 bp insert size of patient no. 8 was prepared. We collected 373 million 2 × 150 bp paired-end reads or 33x coverage on a NovaSeq 6000 instrument. Variant calling was performed using a community-developed pipeline from bcbio nextgen v1.1.6a0 (<https://github.com/bcbio/bcbio-nextgen>, accessed 9 August 2021). In short, the reads were mapped to the human reference genome assembly GRCh38 using BWA-MEM v. 0.7.17 [30]. Variant calling was conducted using GATK HaplotypeCaller v. 3.8 [31] and FreeBayes v. 1.1.0.46 (<https://github.com/freebayes/freebayes>, accessed 9 August 2021) [32] and the union of quality-filtered calls from both tools was used for downstream analysis. The variants were annotated using Ensembl Variant Effect Predictor (VEP) v. 98.3 [33] using in-house scripts. The short-read alignments of *UNC93B1* were visually inspected for structural variants using the integrative genomics viewer (IGV) [34].

## 2.4. Gene Analysis

Numbering within the human *UNC93B1* gene corresponds to the NCBI RefSeq accessions NM\_030930.4 (mRNA) and NP\_112192.2 (protein).

## 3. Results

We successfully amplified and sequenced the last exon of the *UNC93B1* gene in all 536 investigated patients and identified six coding variants with respect to the reference sequence (Table 1, Table S1).

**Table 1.** Details of the six detected *UNC93B1* variants.

dbSNP	HGVS-c	HGVS-p	Alternative Allele Count (Frequency)	gnomAD Allele Frequency
rs7149	c.1557C>G	p.Arg519=	253 (23.6%)	16.0%
rs576491436	c.1629G>A	p.Glu543=	1 (0.1%)	5 × 10 <sup>−4</sup>
rs1308430306	c.1651G>A	p.Asp551Asn	1 (0.1%)	8 × 10 <sup>−6</sup>
n.a.	c.1724_1725delinsAG	p.Pro575Gln	8 (0.7%)	n.a.
rs2375182	c.1768G>T	p.Gly590Trp	4 (0.4%)	0.4%
rs964738111	c.1777G>A	p.Gly593Arg	1 (0.1%)	2 × 10 <sup>−4</sup>

Five variants did not affect the known SDCBP binding motif spanning amino acids 521 to 553 and were not investigated further. Only the p.Asp551Asn variant was located

in the SDCBP binding domain of UNC93B1. In our cohort, one patient carried one copy of the mutant Asn-allele, which was also present once in the current gnomAD dataset of 128,930 alleles.

This female patient developed the first SLE manifestations including polyarthritis, acute cutaneous lupus, antinuclear, and anti-dsDNA antibodies at 16 years of age. In the following years, she developed alopecia, thrombocytopenia, and in particular, recurrent, difficult to treat acute and chronic skin lupus lesions. Additionally, at 30 years of age, she developed neuropsychiatric manifestations and chronic diffuse pain requiring intensive and chronic treatment complicated by drug allergies and recurrent viral infections. The patient was refractory to multiple SLE-targeted treatments. She died at the age of 44 years for reasons seemingly unrelated to SLE. We performed a whole-genome sequencing experiment on this heterozygous patient and evaluated the entire *UNC93B1* gene for the presence of potential additional loss-of-function variants. However, we did not detect anything unusual in the other parts of the gene and concluded that the patient had a fully functional second copy of the *UNC93B1* gene.

#### 4. Discussion

In this study, we tested the hypothesis that genetic variants affecting the SDCBP binding domain of UNC93B1 might cause SLE. This hypothesis was developed from the observation that mouse and dog mutants with such variants exhibit severe autoimmune phenotypes [18,22]. The autoimmune phenotype in ECLE affected dogs with *UNC93B1* variants shows autosomal recessive inheritance [22]. Extrapolating from dogs, a hypothetical human patient with *UNC93B1*-related SLE would, therefore, be required to carry either bi-allelic *UNC93B1* variants abrogating SDCBP binding or a combination of one mutant allele encoding a UNC93B1 protein with impaired SDCBP binding together with a complete loss-of-function allele on the second chromosome. As we did not find such a genotype in our cohort of 536 analyzed SLE patients, we conclude that variants affecting the SDCBP binding domain of UNC93B1 do not represent a common genetic risk factor for SLE. The majority of the patients in the SSCS cohort are of European descent (78%). Hypothetical *UNC93B1* risk alleles might be more common in other populations.

Different from the current knowledge in dogs, the mode of inheritance in *Unc93b1* mutant mice is semi-dominant. Homozygous mutant *Unc93b1*<sup>PKP/PKP</sup> mice have a very severe autoimmune phenotype and die early as a consequence of their systemic autoimmune disease. Heterozygous *Unc93b1*<sup>WT/PKP</sup> mice exhibit only mild signs of autoimmune disease and enhanced TLR7 signaling [18]. Therefore, we cannot exclude the possibility that the heterozygous <sup>551</sup>Asn allele observed in one of our patients contributed to her autoimmune disease, probably in combination with other risk factors.

It has to be cautioned that we focused our analysis on the published SDCBP binding domain of UNC93B1 (amino acids 521–553). To the best of our knowledge, the exact three-dimensional structure of the UNC93B1-SDCBP complex is currently unknown. There might be additional important amino acids in the C-terminal tail or other cytosolic parts of UNC93B1 that are also required for SDCBP binding. The gnomAD database and our study provide evidence that several very rare UNC93B1 alleles with amino acid substitutions in the C-terminal tail exist in the human population. Variants affecting other components of this regulatory pathway, for example, the enzymes mediating phosphorylation or ubiquitination of UNC93B1, might also contribute to autoimmune diseases.

Our results do not exclude the possibility that variants affecting the SDCBP binding domain of UNC93B1 might cause or contribute to other autoimmune phenotypes than SLE in human patients. The investigated patients mostly had adult-onset SLE [29]. *Unc93b1*<sup>PKP/PKP</sup> mice develop signs of systemic inflammation and antinuclear antibodies very early in life [18]. Homozygous *UNC93B1* mutant dogs with ECLE develop a cutaneous form of lupus as juveniles at a few months of age. In most affected dogs, this progresses to a systemic autoimmune disease with frequent involvement of the joints. However, the formation of antinuclear antibodies, a hallmark of SLE, is normally not seen in dogs with

ECLE. These phenotypic differences between UNC93B1 mutant mice and dogs impede an accurate prediction of the resulting phenotype in human patients with homologous *UNC93B1* variants. We therefore think that further studies investigating the presence of genetic variants affecting the C-terminal tail of UNC93B1 in patient cohorts with other autoimmune phenotypes, including familial cases of extremely rare autoimmune disorders, are warranted.

**Supplementary Materials:** The following are available online at <https://www.mdpi.com/article/10.3390/genes12081268/s1>, Table S1: *UNC93B1* genotyping results of 536 patients from the SSCS cohort.

**Author Contributions:** Conceptualization, T.L.; investigation, S.K.; resources, C.R., C.C., M.T., U.H.-D. and J.v.K.; data curation, I.K.; writing—original draft, S.K., C.R. and T.L.; writing—review and editing, S.K., C.R., I.K., C.C., M.T., U.H.-D., J.v.K. and T.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Swiss National Science Foundation, grant number 310030\_200354.

**Institutional Review Board Statement:** The Swiss SLE Cohort Study (SSCS) was approved by the SwissEthics review board (PB\_2017-01434).

**Informed Consent Statement:** All patients gave written informed consent according to the guidelines of the Declaration of Helsinki for conducting the research here described.

**Data Availability Statement:** The data presented in this study is contained within the article and supplementary material.

**Acknowledgments:** The authors are grateful to all patients who participated in this research. We thank the Next Generation Sequencing Platform of the University of Bern for performing the high-throughput sequencing experiments, and the Interfaculty Bioinformatics Unit of the University of Bern for providing high performance computing infrastructure.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Rahman, A.; Isenberg, D.A. Systemic lupus erythematosus. *N. Engl. J. Med.* **2008**, *358*, 929–939. [\[CrossRef\]](#)
2. Domeier, P.P.; Schell, S.L.; Rahman, Z.S. Spontaneous germinal centers and autoimmunity. *Autoimmunity* **2017**, *50*, 4–18. [\[CrossRef\]](#) [\[PubMed\]](#)
3. Whitacre, C.C. Sex differences in autoimmune disease. *Nat. Immunol.* **2001**, *2*, 777–780. [\[CrossRef\]](#) [\[PubMed\]](#)
4. Goulielmos, G.N.; Zervou, M.I.; Vazgiourakis, V.M.; Ghodke-Puranik, Y.; Garyfallos, A.; Niewold, T.B. The genetics and molecular pathogenesis of systemic lupus erythematosus (SLE) in populations of different ancestry. *Gene* **2018**, *668*, 59–72. [\[CrossRef\]](#)
5. Fike, A.J.; Elcheva, I.; Rahman, Z.S.M. The Post-GWAS Era: How to Validate the Contribution of Gene Variants in Lupus. *Curr. Rheumatol. Rep.* **2019**, *21*, 3. [\[CrossRef\]](#) [\[PubMed\]](#)
6. Deane, J.A.; Pisitkun, P.; Barrett, R.S.; Feigenbaum, L.; Town, T.; Ward, J.M.; Flavell, R.A.; Bolland, S. Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. *Immunity* **2007**, *27*, 801–810. [\[CrossRef\]](#) [\[PubMed\]](#)
7. Pisitkun, P.; Deane, J.A.; Difilippantonio, M.J.; Tarasenko, T.; Satterthwaite, A.B.; Bolland, S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. *Science* **2006**, *312*, 1669–1672. [\[CrossRef\]](#)
8. Subramanian, S.; Tus, K.; Li, Q.Z.; Wang, A.; Tian, X.H.; Zhou, J.; Liang, C.; Bartov, G.; McDaniel, L.D.; Zhou, X.J.; et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 9970–9975. [\[CrossRef\]](#)
9. Souyris, M.; Cenac, C.; Azar, P.; Daviaud, D.; Canivet, A.; Grunenwald, S.; Pienkowski, C.; Chaumeil, J.; Mejía, J.E.; Guéry, J.C. TLR7 escapes X chromosome inactivation in immune cells. *Sci. Immunol.* **2018**, *3*, eaap8855. [\[CrossRef\]](#)
10. Shen, N.; Fu, Q.; Deng, Y.; Qian, X.; Zhao, J.; Kaufman, K.M.; Wu, Y.L.; Yu, C.Y.; Tang, Y.; Chen, J.Y.; et al. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 15838–15843. [\[CrossRef\]](#)
11. Raafat, I.I.; El Guindy, N.; Shahin, R.M.H.; Samy, L.A.; El Refai, R.M. Toll-like receptor 7 gene single nucleotide polymorphisms and the risk for systemic lupus erythematosus: A case-control study. *Z. Rheumatol.* **2018**, *77*, 416–420. [\[CrossRef\]](#)
12. Yasutomo, K.; Horiuchi, T.; Kagami, S.; Tsukamoto, H.; Hashimura, C.; Urushihara, M.; Kuroda, Y. Mutation of DNASE1 in people with systemic lupus erythematosus. *Nat. Genet.* **2001**, *28*, 313–314. [\[CrossRef\]](#) [\[PubMed\]](#)
13. Rice, G.; Newman, W.G.; Dean, J.; Patrick, T.; Parmar, R.; Flintoff, K.; Robins, P.; Harvey, S.; Hollis, T.; O'Hara, A.; et al. Heterozygous mutations in *TREX1* cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. *Am. J. Hum. Genet.* **2007**, *80*, 811–815. [\[CrossRef\]](#) [\[PubMed\]](#)



14. Kim, Y.-M.; Brinkmann, M.M.; Paquet, M.-E.; Ploegh, H.L. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. *Nature* **2008**, *452*, 234–238. [[CrossRef](#)] [[PubMed](#)]
15. Casrouge, A.; Zhang, S.Y.; Eidenschenk, C.; Jouanguy, E.; Puel, A.; Yang, K.; Alcais, A.; Picard, C.; Mahfoufi, N.; Nicolas, N.; et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. *Science* **2006**, *314*, 308–312. [[CrossRef](#)]
16. Tabeta, K.; Hoebe, K.; Janssen, E.M.; Du, X.; Georgel, P.; Crozat, K.; Mudd, S.; Mann, N.; Sovath, S.; Goode, J.; et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. *Nat. Immunol.* **2006**, *7*, 156–164. [[CrossRef](#)]
17. Ishida, H.; Asami, J.; Zhang, Z.; Nishizawa, T.; Shigematsu, H.; Ohto, U.; Shimizu, T. Cryo-EM structures of Toll-like receptors in complex with UNC93B1. *Nat. Struct. Mol. Biol.* **2021**, *28*, 173–180. [[CrossRef](#)]
18. Majer, O.; Liu, B.; Kreuk, L.S.M.; Krogan, N.; Barton, G.M. UNC93B1 recruits syntenin-1 to dampen TLR7 signaling and prevent autoimmunity. *Nature* **2019**, *575*, 366–370. [[CrossRef](#)]
19. Saitoh, S.; Miyake, K. Regulatory molecules required for nucleotide-sensing Toll-like receptors. *Immunol. Rev.* **2009**, *227*, 32–43. [[CrossRef](#)]
20. Majer, O.; Liu, B.; Woo, B.J.; Kreuk, L.S.M.; Van Dis, E.; Barton, G.M. Release from UNC93B1 reinforces the compartmentalized activation of select TLRs. *Nature* **2019**, *575*, 371–374. [[CrossRef](#)]
21. Fukui, R.; Saitoh, S.; Kanno, A.; Onji, M.; Shibata, T.; Ito, A.; Onji, M.; Matsumoto, M.; Akira, S.; Yoshida, N.; et al. Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking. *Immunity* **2011**, *35*, 69–81. [[CrossRef](#)] [[PubMed](#)]
22. Leeb, T.; Leuthard, F.; Jagannathan, V.; Kiener, S.; Letko, A.; Roosje, P.; Welle, M.M.; Gailbreath, K.L.; Cannon, A.; Linek, M.; et al. A missense variant affecting the C-terminal tail of UNC93B1 in dogs with exfoliative cutaneous lupus erythematosus (ECLE). *Genes* **2020**, *11*, 159. [[CrossRef](#)] [[PubMed](#)]
23. Olivry, T.; Linder, K.E.; Banovic, F. Cutaneous lupus erythematosus in dogs: A comprehensive review. *BMC Vet. Res.* **2018**, *14*, 132. [[CrossRef](#)] [[PubMed](#)]
24. Vroom, M.W.; Theaker, A.J.; Rest, J.R.; White, S.D. Case report: Lupoid dermatosis in 5 German short-hair pointer. *Vet. Dermatol.* **1995**, *6*, 93–98. [[CrossRef](#)]
25. Bryden, S.L.; White, S.D.; Dunston, S.M.; Burrows, A.K.; Olivry, T. Clinical, histopathological and immunological characteristics of exfoliative cutaneous lupus erythematosus in 25 German short-haired pointers. *Vet. Dermatol.* **2005**, *16*, 239–252. [[CrossRef](#)]
26. Mauldin, E.A.; Morris, D.O.; Brown, D.C.; Casal, M.L. Exfoliative cutaneous lupus erythematosus in German shorthaired pointer dogs: Disease development, progression and evaluation of three immunomodulatory drugs (ciclosporin, hydroxychloroquine, and adalimumab) in a controlled environment. *Vet. Dermatol.* **2010**, *21*, 373–382. [[CrossRef](#)] [[PubMed](#)]
27. Chizzolini, C.; Cohen, C.D.; Eisenberger, U.; Hauser, T.; Hunziker, T.; Leimgruber, A.; Pechula, M.; Ribi, C.; Stoll, T.; Trendelenburg, M.; et al. Towards the Swiss systemic lupus erythematosus cohort study (SSCS). *Rev. Med. Suisse* **2009**, *5*, 808–811. [[PubMed](#)]
28. Ribi, C.; Trendelenburg, M.; Gayet-Ageron, A.; Cohen, C.D.; Dayer, E.; Eisenberger, U.; Hauser, T.; Hunziker, T.; Leimgruber, A.; Lindner, G.; et al. The Swiss Systemic lupus erythematosus Cohort Study (SSCS)-I-Cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland. *Swiss Med. Wkly.* **2014**, *144*, w13990. [[CrossRef](#)]
29. Meier, A.L.; Bodmer, N.S.; Wirth, C.; Bachmann, L.M.; Ribi, C.; Pröbstel, A.K.; Waeber, D.; Jelcic, I.; Steiner, U.C.; Swiss SLE Cohort Study (SSCS). Neuro-psychiatric manifestations in patients with systemic lupus erythematosus: A systematic review and results from the Swiss lupus cohort study. *Lupus* **2021**, *21*, 9612033211025636.
30. Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *arXiv* **2013**, arXiv:1303.3997v2.
31. McKenna, A.; Hanna, M.; Banks, E.; Sivachenko, A.; Cibulskis, K.; Kernytsky, A.; Garimella, K.; Altshuler, D.; Gabriel, S.; Daly, M.; et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* **2010**, *20*, 1297–1303. [[CrossRef](#)] [[PubMed](#)]
32. Garrison, E.; Marth, G. Haplotype-based variant detection from short-read sequencing. *arXiv* **2012**, arXiv:1207.3907.
33. McLaren, W.; Gil, L.; Hunt, S.E.; Riat, H.S.; Ritchie, G.R.; Thormann, A.; Flicek, P.; Cunningham, F. The Ensembl Variant Effect Predictor. *Genome Biol.* **2016**, *17*, 122. [[CrossRef](#)] [[PubMed](#)]
34. Robinson, J.T.; Thorvaldsdóttir, H.; Winckler, W.; Guttman, M.; Lander, E.S.; Getz, G.; Mesirov, J.P. Integrative genomics viewer. *Nat. Biotechnol.* **2011**, *29*, 24–26. [[CrossRef](#)] [[PubMed](#)]